HC Wainwright Issues Pessimistic Outlook for RMTI Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Analysts at HC Wainwright decreased their Q2 2025 earnings per share estimates for shares of Rockwell Medical in a research report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.01) for the quarter, down from their previous forecast of $0.02. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

Other equities analysts have also recently issued reports about the company. RODMAN&RENSHAW upgraded Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. StockNews.com cut Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Rodman & Renshaw started coverage on Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 price target on the stock.

Rockwell Medical Stock Down 1.3 %

Shares of RMTI stock opened at $2.22 on Tuesday. Rockwell Medical has a 1 year low of $1.16 and a 1 year high of $5.15. The stock has a market cap of $71.75 million, a PE ratio of -44.40 and a beta of 1.50. The business’s fifty day moving average is $3.43 and its 200-day moving average is $2.66. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.00 and a current ratio of 2.41.

Hedge Funds Weigh In On Rockwell Medical

A number of hedge funds have recently modified their holdings of the stock. Armistice Capital LLC grew its holdings in shares of Rockwell Medical by 22.5% in the 2nd quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after acquiring an additional 592,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Rockwell Medical by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock worth $1,856,000 after acquiring an additional 43,302 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Rockwell Medical in the 3rd quarter worth $534,000. Walleye Capital LLC acquired a new position in shares of Rockwell Medical in the 3rd quarter worth $435,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock worth $181,000 after acquiring an additional 92,189 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors and hedge funds.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.